VFF - The signal in the noise
News

Bluesky Turns Attie Into Open Social Research Tool

Read original
Share
Bluesky Turns Attie Into Open Social Research Tool

Bluesky has expanded its AI assistant Attie to function as an open social research tool, allowing users to query news, trends, and conversations across Bluesky and other applications built on the AT Protocol. The move positions Attie as a research instrument for analyzing social media data at scale. This represents a shift from a basic assistant toward a platform for structured data exploration.

  • Bluesky's AI assistant Attie now enables users to ask questions about news, trends, and conversations on Bluesky and AT Protocol apps
  • The tool functions as an open social research platform rather than a simple chatbot
  • Users can query across multiple applications within the AT Protocol ecosystem
  • The expansion reflects Bluesky's strategy to leverage its decentralized protocol for data analysis and research

AI assistants that can query social media data at scale are becoming key infrastructure for understanding public discourse and trend detection. By opening Attie as a research tool, Bluesky is positioning itself as a data source for researchers, journalists, and analysts who need structured access to social conversations. This could establish Bluesky as a meaningful alternative to X and other platforms for social intelligence.

Attie's expansion into research tooling creates potential revenue and partnership opportunities for Bluesky through academic licensing, enterprise research subscriptions, and data partnerships. The move also increases platform stickiness by offering utility beyond social networking, potentially attracting researchers and analysts as users.

  • Bluesky is building infrastructure to compete with X and other platforms as a primary source for social data research
  • The AT Protocol's decentralized design may enable broader data access than centralized platforms allow
  • AI-powered research tools could become a standard feature for social platforms seeking to differentiate and monetize user data

Monitor whether academic institutions and research organizations adopt Attie for social science research. Track if Bluesky introduces commercial licensing or enterprise tiers for the tool. Watch for competitive responses from other platforms, particularly X and Meta, regarding their own AI research capabilities.

Share

Subscribe to the newsletter

The latest stories and analysis, delivered to your inbox.

Free. No spam. Unsubscribe any time.

Related stories

Why 89% of AI Gains Aren't Translating to ROI

Why 89% of AI Gains Aren't Translating to ROI

Atlassian research finds that 89% of executives report individual workers are speeding up with AI, yet only 6% can identify specific ROI. The disconnect stems from optimizing individual AI use rather than team-level workflows. High-performing teams share three traits: shared context graphs, redesigned end-to-end processes, and cultures that encourage experimentation.

· VentureBeat AI
OpenAI Details Safety Risks in Long-Horizon AI Models

OpenAI Details Safety Risks in Long-Horizon AI Models

OpenAI has published findings on safety and alignment challenges specific to long-horizon AI models, documenting new risks, observed failures, and improved safeguards developed through iterative deployment. The company shares lessons learned from operating these extended-capability systems in production environments. The work addresses practical safety concerns that emerge when models operate over longer time horizons and decision chains.

· OpenAI
PsiQuantum's Quantum Bet: From Lab to Commercial Reality
TrendingNews

PsiQuantum's Quantum Bet: From Lab to Commercial Reality

PsiQuantum, a UK-founded quantum computing startup, is building a photonic quantum computer designed to solve problems current machines would take millions of years to address. The company has raised $1 billion, is constructing facilities in Chicago and Australia, and is one of only two firms (alongside Microsoft) to reach the third stage of a government quantum evaluation program. Its claims are bold, from reducing drug development timelines to four minutes, but the company now faces a critical prove-it moment as it approaches commercialization.

by James O'Donnell· MIT Technology Review